Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer

International Journal of Gynecological Cancer

Volumn 16, Issue SUPPL. 1, 2006, Pages 236-240

  See, H T ^a   Thomas, D A ^a   Bueso Ramos, C ^a   Kavanagh, J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Erythroleukemia; Ovarian cancer; Paclitaxel

Indexed keywords

BUSULFAN; CARBOPLATIN; CYTARABINE; ERYTHROPOIETIN; FERROUS SULFATE; FLUDARABINE; IDARUBICIN; PACLITAXEL;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; CHROMOSOME ABERRATION; CLINICAL EXAMINATION; CLINICAL FEATURE; CYTOPENIA; CYTOREDUCTIVE SURGERY; DRUG INDUCED CANCER; ERYTHROLEUKEMIA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYSTERECTOMY; IMMUNOSUPPRESSIVE TREATMENT; LEIOMYOSARCOMA; LIVER METASTASIS; MYELODYSPLASTIC SYNDROME; OVARY CARCINOMA; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SALPINGOOOPHORECTOMY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARM; BUSULFAN; CARBOPLATIN; CYTARABINE; FATAL OUTCOME; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; IDARUBICIN; LEIOMYOSARCOMA; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LIVER NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOPLASMS, SECOND PRIMARY; OVARIAN NEOPLASMS; PACLITAXEL; REOPERATION; STEM CELL TRANSPLANTATION; VIDARABINE;

EID: 33645368072     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00491.x     Document Type: Review

References (22)

1. Kantarjian HM Keating MJ. Therapy-related leukemia and myelodysplastic syndrome. Semin Oncol 1987 14 435 43.
2. Thirman MJ Larson RA. Therapy-related myeloid leukemia. Hematol Oncol Clin North Am 1996 10 293 320.
3. Giles FJ Koeffler HP. Secondary myelodysplastic syndromes and leukemias. Curr Opin Hematol 1994 1 256 60.
4. Leone G Mele L Pulsoni A Equitani F Pagano L. The incidence of secondary leukemias. Haematologica 1999 84 937 45.
5. Leone G Voso MT Sica S Morosetti R Pagano L. Therapy related leukemias: susceptibility, prevention and treatment. Leuk Lymphoma 2001 41 255 76.
6. Larson RA Wernli M Le Beau MM Daly KM Pape LH Rowley JD et al. Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine. Blood 1988 72 1333 9.
7. Muggia FM. Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers. Semin Oncol 2004 31 Suppl. 14 17 24.
8. Coleman MP Bell CM Fraser P. Second primary malignancy after Hodgkin's disease, ovarian cancer and cancer of the testis: a population-based cohort study. Br J Cancer 1987 56 349 55.
9. Thigpen JT. Chemotherapy for advanced ovarian cancer: overview of randomized trials. Semin Oncol 2000 27 Suppl. 7 11 6.
10. Thigpen T. First-line therapy for ovarian carcinoma: what's next? Cancer Invest 2004 22 Suppl. 2 21 8.
11. Butour JL Mazard AM Macquet JP. Kinetics of the reaction of cis-platinum compounds with DNA in vitro. Biochem Biophys Res Commun 1985 133 347 53.
12. Alberts DS Dorr RT. New perspectives on an old friend: optimizing carboplatin for the treatment of solid tumors. Oncologist 1998 3 15 34.
13. Piccart MJ Bertelsen K James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000 92 699 708.
14. McGuire WP Hoskins WJ Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996 334 1 6.
15. Shah MA Schwartz GK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 2001 7 2168 81.
16. Travis LB Holowaty EJ Bergfeldt K et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999 340 351 7.
17. Seymour JF Juneja SK Campbell LJ Ellims PH Estey EH Prince HM. Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy. Leukemia 1999 13 1735 40.
18. Park S Picard F Dreyfus F. Erythroleukemia: a need for a new definition. Leukemia 2002 16 1399 401.
19. Smith SM Le Beau MM Huo D et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003 102 43 52.
20. Ballen KK Gilliland DG Guinan EC et al. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant 1997 20 737 43.
21. Vasey PA Kaye SB Thigpen JT. Importance of dose intensity in ovarian cancer. In Gershenson D McGuire WP eds. Ovarian Cancer: Controversies in Treatment. New York Churchill Livingstone 1998 178 81.
22. Pujade-Lauraine E Cure H Battista C et al. High dose chemotherapy in ovarian cancer. Int J Gynecol Cancer 2001 11 Suppl. 1 64 7.